Jung H Lee

US Patent:

7884131, Feb 8, 2011

Filed:

Nov 21, 2005

Appl. No.:

11/284790

Inventors:

Linda Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Baltimore MD, US
Jung Lee - McLean VA, US
Mary Van Elswyk - Longmont CO, US

Assignee:

Martek Biosciences, Corporation - Columbia MD

International Classification:

A61K 31/22
C07C 59/00
C07C 57/00

US Classification:

514549, 514165, 514546, 514560, 562400, 562579, 562512, 554 82, 554227, 554230

Abstract:

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.

US Patent:

7893106, Feb 22, 2011

Filed:

Jan 31, 2007

Appl. No.:

11/669730

Inventors:

Linda Mary Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Colorado Springs CO, US
Jung Lee - McLean VA, US
Dutt Vinjamoori - Chesterfield MO, US

Assignee:

Martek Biosciences, Corporation - Columbia MD

International Classification:

A61K 31/22
C07C 57/00
C07C 59/00

US Classification:

514549, 514164, 514171, 514560, 562579, 562512, 562400, 554230, 554224, 554227

Abstract:

Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

US Patent:

20100130608, May 27, 2010

Filed:

Oct 1, 2009

Appl. No.:

12/572263

Inventors:

Alan Stuart RYAN - Ellicott City MD, US
Edward B. Nelson - Austin TX, US
Jung Lee - McLean VA, US
Krishna Raman - Wilmington DE, US

Assignee:

Martek Biosciences Corporation - Columbia MD

International Classification:

A61K 31/22
A61K 31/202
A61P 3/00

US Classification:

514549, 514560

Abstract:

The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source. In some embodiments, the method comprises administering daily to the subject a dosage form comprising DHA ester substantially free of EPA, wherein the DHA ester is about 60% to about 99.5% (w/w) of the total fatty acid content of the dosage form. In some embodiments, the method comprises administering daily to the subject a dosage form comprising about 200 mg to about 4 g of DHA ester substantially free of EPA. In some embodiments, the foregoing methods also result in a lowering of the amount of total cholesterol in the subject.

US Patent:

20110112191, May 12, 2011

Filed:

Jan 19, 2011

Appl. No.:

13/009218

Inventors:

Linda Mary Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MS, US
James Flatt - Colorado Springs CO, US
Jung Lee - McLean VA, US
Dutt Vinjamoori - Chesterfield MO, US

Assignee:

Martek Biosciences, Corporation - Columbia MD

International Classification:

A61K 31/202
C07C 59/42
A61P 29/00
A61P 25/00

US Classification:

514560, 554219

Abstract:

Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

US Patent:

20110178047, Jul 21, 2011

Filed:

Dec 29, 2010

Appl. No.:

12/981261

Inventors:

Linda Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Colorado Springs CO, US
Jung Lee - McLean VA, US
Mary Van Elswyk - Longmont CO, US

Assignee:

MARTEK BIOSCIENCES CORPORATION - Columbia MD

International Classification:

A61K 31/202
C07C 59/42
A61K 31/616
A61P 29/00
A61P 25/28

US Classification:

514163, 554219, 514560

Abstract:

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.

US Patent:

20110190389, Aug 4, 2011

Filed:

Feb 20, 2008

Appl. No.:

12/531344

Inventors:

Linda Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Colorado Springs CO, US
Jung Lee - McLean VA, US
Dutt Vinjamoori - Chesterfield MO, US
Mary Van Elswyk - Longmont CO, US

International Classification:

A61K 31/336
A61K 31/202
C07C 57/03
A61P 29/00
C12P 7/64
C12P 17/02
C07D 303/38
A61P 25/28

US Classification:

514475, 514560, 554124, 435134, 435123, 549561

Abstract:

Disclosed are novel oxylipins, referred to herein as docosanoids and eicosanoids, that are derived from C22 polyunsaturated fatty acids and from C20 polyunsaturated fatty acids, respectively, and methods of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6), docosatrienoic acid (C22:3n-3) (DTrAn-3), docosadienoic acid (C22:2n-6) (DDAn-6), eicosatrienoic acid (C20:3n-3) (ETrAn-3) eicosapentaenoic acid and arachidonic acid as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUF A)-rich oils and compositions that contain enhanced and effective amounts of LCPUF A-derived oxylipins, and particularly, docosanoids.

US Patent:

20110200644, Aug 18, 2011

Filed:

Feb 18, 2011

Appl. No.:

13/031172

Inventors:

Jung LEE - McLean VA, US
Bernard A. MIKRUT - Lake Bluff IL, US
Xuejun TANG - Ellicott City MD, US

Assignee:

Martek Biosciences Corporation - Columbia MD

International Classification:

A61K 9/107
A61K 31/232
A61P 19/02
A61P 1/16

US Classification:

424400, 514549

Abstract:

The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid ethyl ester (DHA-EE) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration.

US Patent:

20110200645, Aug 18, 2011

Filed:

Feb 18, 2011

Appl. No.:

13/031178

Inventors:

Jung LEE - McLean VA, US
Bernard A. Mikrut - Lake Bluff IL, US
Xuejun Tang - Ellicott City MD, US

Assignee:

Martek Biosciences Corporation - Columbia MD

International Classification:

A61K 9/107
A61K 31/202
A61P 9/10
A61P 19/02
A61P 1/16
A61P 9/04

US Classification:

424400, 514560

Abstract:

The present invention is directed to an emulsion comprising an emulsifier, an isotonic agent and a docosahexaenoic acid free fatty acid (DHA-FFA) wherein the emulsion is substantially free of eicosapentaenoic acid (EPA) and is suitable for parenteral administration.